Megan Thistle, OD
NPI 1659734911 · Optometrist · Menasha, WI
Enrolled with Medicare as Practitioner - Optometry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1659734911
- Entity type
- Individual
- Primary specialty
- OptometristEye and Vision Services Providers
- Credential
- OD
- Sex
- Female
- Sole proprietor
- Yes
- License
- 3507-35 (WI)
Specialties & taxonomies
Eye and Vision Services Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure28% of score
10 yrs in NPPES registry
- Profile completeness28% of score
100% of core fields populated
- Practice footprint17% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)28% of score
267 Medicare services, 2024 (ranked within specialty)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Complete Exam of Visual System92014 | 60 | $119 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 60 | $85 |
| Exam to Measure Eye Deviation and Range of Motion92060 | 48 | $58 |
| New Patient Complete Exam of Visual System92004 | 25 | $137 |
| Imaging of Retina92134 | 24 | $38 |
| New Patient Office Or Other Outpatient Visit With Moderate Level of Medical Decision Making, If Using Time, 45 Minutes Or More99204 | 19 | $149 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 7 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 160 | 45 |
| Brimonidine Tartrate | 29 | — |
| Lifitegrastbrand: Xiidra | 23 | — |
| Neomycin/Polymyxin B/Dexamethabrand: Neomycin-Polymyxin-Dexameth | 21 | 17 |
| Prednisolone Acetate | 14 | — |
| Cyclosporinebrand: Restasis | 14 | — |
| Timolol Maleate | 11 | — |
These counts cover prescriptions paid through Medicare Part D in 2024 — they include cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means , never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Practice location
Mailing address
Registry dates
- Enumerated
- 2016-04-03
- Last updated
- 2024-12-20
- Certified
- 2024-12-20
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.